Humana (NYSE:HUM) had its price target lifted by Oppenheimer from $275.00 to $305.00 in a research report released on Thursday. The brokerage currently has an outperform rating on the insurance provider’s stock. Oppenheimer also issued estimates for Humana’s Q1 2018 earnings at $3.18 EPS and Q4 2019 earnings at $2.99 EPS.
Several other equities analysts also recently commented on the company. BMO Capital Markets upped their price objective on Humana from $290.00 to $300.00 and gave the company an outperform rating in a research report on Friday, November 10th. Cowen reiterated a buy rating and issued a $285.00 target price on shares of Humana in a report on Wednesday, December 13th. Royal Bank of Canada reiterated a sector perform rating and issued a $242.00 target price (down from $245.00) on shares of Humana in a report on Thursday, November 9th. Zacks Investment Research cut Humana from a strong-buy rating to a hold rating in a report on Friday, January 19th. Finally, Credit Suisse Group lowered their target price on Humana from $256.00 to $246.00 and set a neutral rating for the company in a report on Friday, November 10th. Eight investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Humana currently has a consensus rating of Buy and a consensus target price of $269.68.
Humana (HUM) opened at $265.32 on Thursday. The company has a market capitalization of $37,903.62, a price-to-earnings ratio of 22.70, a price-to-earnings-growth ratio of 1.54 and a beta of 0.93. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.85 and a quick ratio of 1.61. Humana has a 12-month low of $203.36 and a 12-month high of $293.35.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 27th. Investors of record on Friday, March 30th will be paid a dividend of $0.50 per share. This is a boost from Humana’s previous quarterly dividend of $0.40. This represents a $2.00 dividend on an annualized basis and a dividend yield of 0.75%. The ex-dividend date is Wednesday, March 28th. Humana’s dividend payout ratio is 9.59%.
Humana announced that its Board of Directors has authorized a share repurchase program on Thursday, December 14th that authorizes the company to buyback $3.00 billion in shares. This buyback authorization authorizes the insurance provider to repurchase shares of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board of directors believes its stock is undervalued.
In related news, VP Timothy S. Huval sold 1,382 shares of the company’s stock in a transaction on Tuesday, December 19th. The stock was sold at an average price of $246.04, for a total transaction of $340,027.28. Following the completion of the sale, the vice president now directly owns 11,557 shares in the company, valued at approximately $2,843,484.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Jody L. Bilney sold 7,054 shares of the company’s stock in a transaction on Monday, December 18th. The stock was sold at an average price of $247.89, for a total value of $1,748,616.06. Following the sale, the senior vice president now owns 11,704 shares of the company’s stock, valued at $2,901,304.56. The disclosure for this sale can be found here. Insiders have sold a total of 10,115 shares of company stock valued at $2,501,627 over the last 90 days. 0.80% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently modified their holdings of HUM. Shelton Capital Management purchased a new stake in shares of Humana during the 2nd quarter worth $287,000. Gotham Asset Management LLC lifted its stake in shares of Humana by 6.3% during the 2nd quarter. Gotham Asset Management LLC now owns 20,914 shares of the insurance provider’s stock worth $5,032,000 after purchasing an additional 1,234 shares during the last quarter. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Humana during the 2nd quarter worth $10,323,000. Bank of Nova Scotia lifted its stake in shares of Humana by 838.2% during the 2nd quarter. Bank of Nova Scotia now owns 32,632 shares of the insurance provider’s stock worth $7,852,000 after purchasing an additional 29,154 shares during the last quarter. Finally, Scotia Capital Inc. lifted its stake in shares of Humana by 4.8% during the 2nd quarter. Scotia Capital Inc. now owns 2,200 shares of the insurance provider’s stock worth $529,000 after purchasing an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 94.39% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Humana (HUM) PT Raised to $305.00 at Oppenheimer” was first published by Ticker Report and is the property of of Ticker Report. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3191912/humana-hum-pt-raised-to-305-00-at-oppenheimer.html.
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.